Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) · earnings preview
Quarter
Q3
EPS estimate to actual
-$0.55
Revenue estimate to actual
$21.3M
At a glance
Key takeaways
01Ginkgo Bioworks (DNA) will report Q3 2026 earnings on November 05 after market close with expected EPS of -$0.55, worsening from -$0.00 last year.
02Revenue is projected at $21.3M, representing year-over-year growth, though the company continues to report negative earnings.
03The stock trades at $11.66 with a market capitalization of $539.9M as of the article date.
04Recent quarterly results show worsening EPS trends, with Q2 missing estimates by 31.4%, suggesting deteriorating profitability.
Earnings Results
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is scheduled to report its Q3 earnings results on November 05, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.55, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at $21.3M, up from a year ago.
Company Overview
The stock currently trades at $11.66 with a market capitalization of $539.9M.
Ahead of Ginkgo Bioworks Holdings, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Ginkgo Bioworks Holdings, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.